Table 4.
COX Analysis of SPFS
| System-IPFS (pBM Group) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | |||||||
| HR | 95% CI | p value | HR | 95% CI | p value | |||
| Down | Up | Down | Up | |||||
| Age (≥70 vs <70) | 1.248 | 0.441 | 3.531 | 0.667 | ||||
| Histologic type | ||||||||
| Adeno vs Squamous | 1.12 | 0.431 | 2.913 | 0.815 | ||||
| Adeno vs Other | 1.204 | 0.852 | 1.702 | 0.293 | ||||
| ICIs line, ≥3 vs <3 | 1.952 | 1.068 | 3.567 | 0.03 | ||||
| ECOG PS, 2 vs 0–1 | 3.698 | 1.777 | 7.696 | <0.001* | 3.264 | 1.766 | 6.033 | <0.001* |
| Size of intracranial lesion (maximum diameter) (>3cm vs <3cm) | 1.096 | 0.557 | 2.159 | 0.791 | ||||
| Edema size (>3cm vs <3cm) | 0.972 | 0.503 | 1.877 | 0.933 | ||||
| Number of total lesions | 1.27 | 0.718 | 2.246 | 0.412 | ||||
| Meningeal metastasis | 1.408 | 0.668 | 2.966 | 0.369 | ||||
| GPA score | ||||||||
| 0–1 vs 1.5–2.5 | 0.995 | 0.54 | 1.834 | 0.987 | ||||
| 0–1 vs 3 | 2.423 | 0.538 | 10.911 | 0.249 | ||||
| Combined with radiotherapy (yes vs no) | 0.862 | 0.484 | 1.536 | 0.615 | ||||
| ICIs regimes (monotherapy vscombined therapy) | 0.368 | 0.206 | 0.657 | 0.001* | 0.52 | 0.279 | 0.967 | 0.039* |
| Mutation (EGFR mutation vs other mutation) | 0.791 | 0.272 | 2.3 | 0.667 | ||||
| Liver metastasis | 1.210 | 0.372 | 3.934 | 0.751 | ||||
| Gender, n (%) (male vs female) | 1.226 | 0.647 | 2.325 | 0.532 | ||||
Note: *p<0.05.
Abbreviations: ICIs, immune checkpoint inhibitors; DS-GPA, disease-specific graded prognostic assessment; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; pBM, patients with brain metastasis prior to ICIs treatment.